Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esketamine plus cervical plexus block for postoperative depression and anxiety after thyroid cancer surgery
ChiCTR2200066199Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital of Gannan Medical University
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of esketamine in major depressive disorder (MDD), anxiety disorder and thyroid cancer (2 arms), sponsored by First Affiliated Hospital of Gannan Medical University. Primary endpoints: Depression scores, Anxiety scores and 2 more. Planned start Aug 2022; status: not yet recruiting.
02
Drugs
esketamine
03
Conditions
major depressive disorder (MDD)anxiety disorderthyroid cancer
Beyond the preview
Go deeper on ChiCTR2200066199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200066199.